Trial Profile
A Pivotal, Multicenter, Open-label, Randomized Withdrawal, Non-Treatment Concurrent Control Study to Assess the Safety, Tolerability, and Efficacy of Cabaletta® in OPMD Patients Who Participated in Study BBCO-001
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trehalose (Primary)
- Indications Oculopharyngeal muscular dystrophy
- Focus Therapeutic Use
- Acronyms HOPEMD
- Sponsors Bioblast Pharma
- 14 Feb 2018 Status changed from active, no longer recruiting to completed.
- 21 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 21 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Aug 2017.